These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 25361868

  • 1. Transdermal immunization using solid-in-oil nanodispersion with CpG oligodeoxynucleotide adjuvants.
    Kitaoka M, Naritomi A, Hirakawa Y, Kamiya N, Goto M.
    Pharm Res; 2015 Apr; 32(4):1486-92. PubMed ID: 25361868
    [Abstract] [Full Text] [Related]

  • 2. Changes in immune responses to antigen applied to tape-stripped skin with CpG-oligodeoxynucleotide in NC/Nga mice.
    Inoue J, Yotsumoto S, Sakamoto T, Tsuchiya S, Aramaki Y.
    Pharm Res; 2005 Oct; 22(10):1627-33. PubMed ID: 16180119
    [Abstract] [Full Text] [Related]

  • 3. Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice.
    Tada R, Muto S, Iwata T, Hidaka A, Kiyono H, Kunisawa J, Aramaki Y.
    BMC Res Notes; 2017 Jan 26; 10(1):68. PubMed ID: 28126014
    [Abstract] [Full Text] [Related]

  • 4. Effect of oral administration of CpG ODN-OVA on WBB6F1-W/Wv mice.
    Teshima R, Okunuki H, Sato Y, Akiyama H, Maitani T, Sawada J.
    Allergol Int; 2006 Mar 26; 55(1):43-8. PubMed ID: 17075285
    [Abstract] [Full Text] [Related]

  • 5. Time course study of the antigen-specific immune response to a PLGA microparticle vaccine formulation.
    Wang Q, Tan MT, Keegan BP, Barry MA, Heffernan MJ.
    Biomaterials; 2014 Sep 26; 35(29):8385-93. PubMed ID: 24986256
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Orally administered OVA/CpG-ODN induces specific mucosal and systemic immune response in young and aged mice.
    Alignani D, Maletto B, Liscovsky M, Rópolo A, Morón G, Pistoresi-Palencia MC.
    J Leukoc Biol; 2005 Jun 26; 77(6):898-905. PubMed ID: 15758079
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Induction of a balanced Th1/Th2 immune responses by co-delivery of PLGA/ovalbumin nanospheres and CpG ODNs/PEI-SWCNT nanoparticles as TLR9 agonist in BALB/c mice.
    Ebrahimian M, Hashemi M, Maleki M, Abnous K, Hashemitabar G, Ramezani M, Haghparast A.
    Int J Pharm; 2016 Dec 30; 515(1-2):708-720. PubMed ID: 27989827
    [Abstract] [Full Text] [Related]

  • 13. CpG-oligodinucleotides as an effective adjuvant in pigs for intramuscular immunizations.
    Van der Stede Y, Verdonck F, Vancaeneghem S, Cox E, Goddeeris BM.
    Vet Immunol Immunopathol; 2002 May 30; 86(1-2):31-41. PubMed ID: 11943328
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Vaccinations with T-helper type 1 directing adjuvants have different suppressive effects on the development of allergen-induced T-helper type 2 responses.
    Trujillo-Vargas CM, Mayer KD, Bickert T, Palmetshofer A, Grunewald S, Ramirez-Pineda JR, Polte T, Hansen G, Wohlleben G, Erb KJ.
    Clin Exp Allergy; 2005 Aug 30; 35(8):1003-13. PubMed ID: 16120081
    [Abstract] [Full Text] [Related]

  • 16. Double-stranded phosphodiester cytosine-guanine oligodeoxynucleotide complexed with calcium phosphate as a potent vaccine adjuvant for activating cellular and Th1-type humoral immunities.
    Hanagata N, Li X, Chen MH, Li J, Hattori S.
    Int J Nanomedicine; 2018 Aug 30; 13():43-62. PubMed ID: 29317815
    [Abstract] [Full Text] [Related]

  • 17. Dual role of CpG as immune modulator and physical crosslinker in ovalbumin loaded N-trimethyl chitosan (TMC) nanoparticles for nasal vaccination.
    Slütter B, Jiskoot W.
    J Control Release; 2010 Nov 20; 148(1):117-121. PubMed ID: 20600405
    [Abstract] [Full Text] [Related]

  • 18. The STING activator c-di-AMP exerts superior adjuvant properties than the formulation poly(I:C)/CpG after subcutaneous vaccination with soluble protein antigen or DEC-205-mediated antigen targeting to dendritic cells.
    Volckmar J, Knop L, Stegemann-Koniszewski S, Schulze K, Ebensen T, Guzmán CA, Bruder D.
    Vaccine; 2019 Aug 14; 37(35):4963-4974. PubMed ID: 31320219
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.